U0126, a mitogen?activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up?regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F14%3A33150321" target="_blank" >RIV/61989592:15310/14:33150321 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11160/14:10282322 RIV/61989592:15110/14:33150321
Result on the web
<a href="http://dx.doi.org/10.1007/s00204-014-1254-2" target="_blank" >http://dx.doi.org/10.1007/s00204-014-1254-2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00204-014-1254-2" target="_blank" >10.1007/s00204-014-1254-2</a>

Result language
angličtina
Original language name
U0126, a mitogen?activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up?regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells
Original language description
We report that U0126 is an atypical PXR ligand that via direct (binding and activation of PXR) and indirect (SHP dowregulation) mechanisms selectively restores CYP3A genes in HepG2 cells.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—

Project
<a href="/en/project/GAP303%2F12%2F0472" target="_blank" >GAP303/12/0472: Novel mechanisms of CYP3A4 enzyme regulation based on posttranslational modification of nuclear receptors - implications for pharmacotherapy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)